Neoplasms, Second Primary

"Neoplasms, Second Primary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.

Descriptor ID	D016609
MeSH Number(s)	C04.692
Concept/Terms	Neoplasms, Second Primary Neoplasms, Second Primary Neoplasm, Second Primary Second Primary Neoplasm Metachronous Second Primary Neoplasms Neoplasms, Metachronous Second Primary Neoplasms, Metachronous Second Malignancy Malignancies, Second Malignancy, Second Second Malignancies Second Neoplasm Neoplasm, Second Neoplasms, Second Second Neoplasms Second Primary Neoplasms Metachronous Neoplasms Metachronous Neoplasm Neoplasm, Metachronous Neoplasms, Metachronous Second Primary Neoplasms, Therapy-Associated Neoplasms, Therapy-Associated Neoplasm, Therapy-Associated Neoplasms, Therapy Associated Therapy-Associated Neoplasm Neoplasms, Treatment-Associated Neoplasm, Treatment-Associated Neoplasms, Treatment Associated Treatment-Associated Neoplasm Neoplasms, Treatment-Related Neoplasm, Treatment-Related Neoplasms, Treatment Related Treatment-Related Neoplasm Therapy-Related Neoplasms Therapy Related Neoplasms Treatment-Associated Neoplasms Treatment Associated Neoplasms Treatment-Related Neoplasms Treatment Related Neoplasms Neoplasms, Therapy-Related Neoplasm, Therapy-Related Neoplasms, Therapy Related Therapy-Related Neoplasm Therapy-Associated Neoplasms Therapy Associated Neoplasms Therapy-Associated Cancer Therapy-Associated Cancer Cancer, Therapy-Associated Cancers, Therapy-Associated Therapy Associated Cancer Therapy-Associated Cancers Therapy-Related Cancer Cancer, Therapy-Related Cancers, Therapy-Related Therapy Related Cancer Therapy-Related Cancers Treatment-Related Cancer Cancer, Treatment-Related Cancers, Treatment-Related Treatment Related Cancer Treatment-Related Cancers Treatment-Associated Cancer Cancer, Treatment-Associated Cancers, Treatment-Associated Treatment Associated Cancer Treatment-Associated Cancers Cancer, Second Primary Cancer, Second Primary Cancers, Second Primary Second Primary Cancer Second Primary Cancers Second Cancer Cancer, Second Cancers, Second Second Cancers

Below are MeSH descriptors whose meaning is more general than "Neoplasms, Second Primary".

Diseases [C]
Neoplasms [C04]
Neoplasms, Second Primary [C04.692]

Below are MeSH descriptors whose meaning is related to "Neoplasms, Second Primary".

Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Second Primary".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasms, Second Primary" by people in this website by year, and whether "Neoplasms, Second Primary" was a major or minor topic of these publications.

Bar chart showing 60 publications over 24 distinct years, with a maximum of 6 publications in 2001 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	1	2
1998	2	0	2
1999	2	0	2
2000	0	1	1
2001	5	1	6
2002	1	0	1
2004	2	0	2
2006	2	1	3
2007	1	1	2
2008	4	1	5
2009	3	1	4
2010	1	1	2
2011	2	0	2
2012	1	0	1
2013	1	0	1
2014	3	0	3
2015	0	2	2
2016	2	0	2
2017	1	0	1
2018	3	1	4
2019	3	1	4
2020	1	0	1
2021	1	0	1
2022	6	0	6

Below are the most recent publications written about "Neoplasms, Second Primary" by people in Profiles.

Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2?and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 11; 176:155-163.

View in: PubMed
Ripa V, Smith F, Goodman JW. Case of metastatic epithelioid haemangioendothelioma from an unknown primary site associated with membranous nephropathy and hypercoagulable state. BMJ Case Rep. 2022 Aug 22; 15(8).

View in: PubMed
Goldberg RM, Adams R, Buyse M, Eng C, Grothey A, Andr? T, Sobrero AF, Lichtman SM, Benson AB, Punt CJA, Maughan T, Burzykowski T, Sommeijer D, Saad ED, Shi Q, Coart E, Chibaudel B, Koopman M, Schmoll HJ, Yoshino T, Taieb J, Tebbutt NC, Zalcberg J, Tabernero J, Van Cutsem E, Matheson A, de Gramont A. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. J Natl Cancer Inst. 2022 06 13; 114(6):819-828.

View in: PubMed
Yang JCH, Brose MS, Castro G, Kim ES, Lassen UN, Leyvraz S, Pappo A, L?pez-R?os F, Reeves JA, Fellous M, Penault-Llorca F, Rudzinski ER, Tabatabai G, Vassal G, Drilon A, Trent J. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. BMC Cancer. 2022 Jun 07; 22(1):625.

View in: PubMed
Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, El-Ashry D, Zhang Q, Gerratana L, Zhang Y, Cristofanilli M, Montanez MA, Sundd P, Wallace CT, Watkins SC, Fumagalli C, Guerini-Rocco E, Zhu L, Tseng GC, Wagle N, Carroll JS, Jank P, Denkert C, Karsten MM, Blohmer JU, Park BH, Lucas PC, Atkinson JM, Lee AV, Oesterreich S. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Res. 2022 04 01; 82(7):1321-1339.

View in: PubMed
Seedor RS, Orloff M. Treatment of Metastatic Melanoma in the Elderly. Curr Oncol Rep. 2022 07; 24(7):825-833.

View in: PubMed
Abugideiri M, Janopaul-Naylor J, Switchenko J, Tian S, Read W, Press R, Oskouei S, Reimer N, Ferris M, Cassidy RJ, Behera M, Monson D, Landry J, Godette KD, Patel PR. Impact of Metastasectomy and Aggressive Local Therapy in Newly Diagnosed Metastatic Soft Tissue Sarcoma: An Analysis of the NCDB. Ann Surg Oncol. 2022 Jan; 29(1):649-659.

View in: PubMed
Parisio K, Mangum DS, Powell J. A novel and successful therapeutic approach in the treatment of a patient with simultaneous relapsed Ewing sarcoma and therapy-related acute myeloid leukemia. Pediatr Blood Cancer. 2020 07; 67(7):e28240.

View in: PubMed
Jain V, Hwang WT, Venigalla S, Nead KT, Lukens JN, Mitchell TC, Shabason JE. Association of Age with Efficacy of Immunotherapy in Metastatic Melanoma. Oncologist. 2020 02; 25(2):e381-e385.

View in: PubMed
Gonsalves CF, Eschelman DJ, Adamo RD, Anne PR, Orloff MM, Terai M, Hage AN, Yi M, Chervoneva I, Sato T. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. Radiology. 2019 10; 293(1):223-231.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement